Peptides for Men: A Research Overview (UK 2026)

Peptide research has increasingly focused on male-specific physiology, with particular attention to hormonal regulation, body composition, sexual function, and age-related decline in androgen and growth hormone pathways. This overview covers the most extensively researched peptides in male-focused research contexts — their mechanisms, evidence base, and relevance to male endocrinology and physiology.

Research disclaimer: All peptides discussed are for laboratory and research use only. They are not approved for human therapeutic use. This content is for educational and research purposes only. All research must be conducted in appropriate institutional settings with proper oversight.

GH Axis Peptides: The Most Researched Category in Male Studies

The growth hormone (GH) axis declines progressively with age in men — a process termed somatopause — with GH pulse amplitude and IGF-1 levels falling significantly after the mid-30s. This decline is associated with increased visceral adiposity, reduced lean mass, impaired sleep quality, and decreased tissue regeneration capacity. Research into GH secretagogue peptides has been driven in large part by the desire to understand whether restoring GH axis activity can attenuate these changes.

GHRP compounds (Growth Hormone Releasing Peptides) stimulate GH release by activating ghrelin receptors on pituitary somatotrophs. GHRH analogues (Growth Hormone Releasing Hormone) activate a complementary receptor on the same cells, producing synergistic GH release when combined. This GHRP+GHRH combination is one of the most studied peptide protocols in adult male physiology research.

Key compounds in this category include Ipamorelin (selective GHRP with minimal cortisol/prolactin spillover), GHRP-6 (potent but less selective), Sermorelin (GHRH analogue closely mimicking endogenous GHRH), and CJC-1295 (longer-acting GHRH analogue available with and without albumin-binding DAC modification).

PT-141 (Bremelanotide): Male Sexual Function Research

PT-141 is a synthetic melanocortin receptor agonist that has been specifically studied for male sexual dysfunction. Unlike phosphodiesterase inhibitors (sildenafil, tadalafil) that work through vascular mechanisms, PT-141 acts centrally — activating MC4R receptors in the hypothalamus to initiate neural pathways associated with sexual arousal.

This central mechanism makes PT-141 relevant to research on psychogenic erectile dysfunction and hypoactive sexual desire disorder in men — cases where the underlying issue is neurogenic rather than vascular. Clinical trials (leading to FDA approval as Vyleesi for female HSDD) demonstrated PT-141 increases subjective arousal and genital engorgement through CNS-mediated mechanisms in both male and female subjects.

For male-focused research, PT-141’s central mechanism and rapid onset (~30-60 minutes post-administration) make it a useful tool for studying the neuroendocrine basis of male sexual function independently of vascular pathways.

IGF-1 LR3: Anabolic Signalling Research

IGF-1 (Insulin-like Growth Factor 1) is the primary downstream mediator of growth hormone’s anabolic effects, produced predominantly in the liver in response to GH stimulation. IGF-1 LR3 is a long-acting synthetic analogue with reduced affinity for IGF-binding proteins, extending its bioavailability and duration of action compared to native IGF-1.

Male-focused research with IGF-1 LR3 has centred on its effects on skeletal muscle protein synthesis, satellite cell activation (the muscle stem cells responsible for repair and hypertrophy), and connective tissue metabolism. IGF-1 signalling through the PI3K/Akt/mTOR pathway is a key anabolic cascade, and IGF-1 LR3’s extended half-life makes it a useful tool for studying sustained IGF-1 receptor activation in muscle biology models.

BPC-157: Musculoskeletal Repair in Male Research Populations

Body Protective Compound 157 has attracted substantial interest in male sports medicine and musculoskeletal research, driven by its demonstrated tendon healing effects in animal models. Male populations bear disproportionate rates of tendon injuries (Achilles, patellar, rotator cuff) due to higher participation in high-load physical activities and sports.

BPC-157 research in male animal models demonstrates: accelerated tendon-to-bone healing with improved tensile strength, upregulation of VEGF and FGFR2 expression supporting angiogenesis at injury sites, reduced inflammatory cytokine expression in damaged tissue, and both oral and systemic administration efficacy in gastrointestinal models. The compound’s stability in gastric acid (unlike most peptides) has made it relevant to gut health research specifically in the context of NSAID-induced damage common in male athletes.

Follistatin: Muscle Development Research

Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin — the primary negative regulator of skeletal muscle mass. By binding and neutralising myostatin, follistatin effectively removes the “brake” on muscle development. This mechanism has made it a subject of significant research interest in muscle wasting conditions (sarcopenia, cachexia, muscular dystrophy) where reducing myostatin signalling is a therapeutic target.

Male-focused research on follistatin has investigated its role in maintaining muscle mass with age, particularly in the context of androgen decline. Testosterone and follistatin appear to have synergistic effects on muscle protein synthesis, and age-related declines in both hormones may compound to accelerate sarcopenia in older men.

MOTS-C: Mitochondrial Peptide Research

MOTS-C is a mitochondria-derived peptide encoded in the 12S rRNA of mitochondrial DNA — the first peptide known to be encoded in the mitochondrial genome and exert nuclear gene regulatory effects. Its discovery has opened a new category of peptide research focused on mitochondria-to-nucleus signalling.

Male-focused MOTS-C research has centred on metabolic regulation, insulin sensitivity, and exercise performance. Studies demonstrate that MOTS-C levels are higher in younger males and decline with age — mirroring other hormonal declines of the male ageing trajectory. Exercise increases circulating MOTS-C, suggesting it may act as a signal mediating some of exercise’s metabolic benefits. Research in aged male animal models shows MOTS-C administration restores insulin sensitivity to levels observed in younger animals.

Tesamorelin: Visceral Adiposity Research

Tesamorelin is a stabilised GHRH analogue that has received FDA approval for the specific indication of HIV-associated lipodystrophy — a condition characterised by pathological visceral fat accumulation. This is the only GHRH-class peptide with approved clinical use, making it particularly relevant to researchers investigating visceral adiposity in male populations.

Visceral fat accumulation is specifically associated with male hormonal decline — testosterone deficiency and GH deficiency both independently drive visceral fat accretion, and the combination is synergistic. Tesamorelin research in male subjects demonstrates significant visceral fat reduction, improved lipid profiles, and improved insulin sensitivity without proportional effects on subcutaneous fat or significant adverse metabolic effects.

Thymosin Alpha-1: Immune Research in Male Populations

Thymosin Alpha-1 (Tα1) is an endogenous thymic peptide that modulates innate and adaptive immune function. It has regulatory approval in several countries for viral hepatitis and as an adjuvant in cancer immunotherapy. Male immune function shows distinct patterns from female immune responses — generally lower innate immune responses and different patterns of autoimmune susceptibility — making male-specific immune research with Tα1 a meaningful category.

Research in male subjects has examined Tα1’s effects on natural killer cell activity, T cell proliferation, and cytokine modulation. Studies in male cancer patients receiving chemotherapy have shown Tα1 attenuates immunosuppression and may reduce infection risk during treatment — a significant quality-of-life and survival benefit that has driven its use in oncological supportive care protocols in some regions.

Key Research Design Considerations for Male-Focused Peptide Studies

Male-focused peptide research requires consideration of several physiological variables that differ from mixed or female-focused study designs:

Testosterone status is a major confounding variable in male metabolic and body composition research. Hypogonadal men respond differently to GH axis peptides than eugonadal men. Studies should document testosterone levels at baseline and control for this variable. Age is a powerful modifier of GH axis, IGF-1, and gonadal hormone levels in men — controlling for age or stratifying by decade is important for meaningful interpretation. Seasonal variation in testosterone levels (higher in autumn/winter in temperate climates) can confound studies that span seasons without controlling for collection timing. Training status significantly affects GH pulse amplitude, IGF-1 baseline, and response to secretagogue peptides — trained athletes have blunted GH responses to secretagogues compared to sedentary controls, which may reflect receptor regulation from higher basal GH activity.